Last reviewed · How we verify
NCT04622670
Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer
NA trial testing Media Intervention in Cervical Adenocarcinoma in 40 participants. Participants enrolled and being followed up; not accepting new ones.
31 January 2027
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 10 March 2020 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 January 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Media Intervention
- Quality-of-Life Assessment
- Questionnaire Administration
- Survey Administration
- Yoga
Conditions studied
- Cervical Adenocarcinoma — all drugs for Cervical Adenocarcinoma →
- Cervical Adenosquamous Carcinoma — all drugs for Cervical Adenosquamous Carcinoma →
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified — all drugs for Cervical Squamous Cell Carcinoma, Not Otherwise Specified →
- Stage IB2 Cervical Cancer FIGO 2018 — all drugs for Stage IB2 Cervical Cancer FIGO 2018 →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, female only, with Cervical Adenocarcinoma or Cervical Adenosquamous Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies how well yoga therapy works during chemotherapy and radiation treatment in improving physical and emotional well-being in patients with stage IB2-IIIB cervical cancer. Yoga therapy may help to balance the mind and body through exercise, meditation (focusing thoughts), and control of breathing and emotions.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exploring prehabilitation interventions for patients with gynaecological cancer undergoing radiotherapy: A scoping review.
McGladrigan E, Wrench E, Dean E, O'Neil A, et al · · 2025 · cited 2× · PMID 40080513 · DOI 10.1371/journal.pone.0319518
Verify or expand the search:
- PubMed search for NCT04622670
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Media Intervention
Trials testing the same drug.
- NCT06639958 — A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home · NA · suspended
- NCT06541158 — Transportation for Cancer Care Navigation Tool for Reducing Travel Barriers Among Patients With Solid Tumors Receiving R · NA · recruiting
- NCT06410209 — A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in H · Phase 2 · recruiting
- NCT05786456 — e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic C · NA · active not recruiting
- NCT06342453 — CREATE: Art for Children With Cancer · NA · recruiting
Other recruiting trials for Cervical Adenocarcinoma
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT06543576 — External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cer · Phase 1, PHASE2 · recruiting
- NCT06654011 — IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Tr · Phase 2 · recruiting
- NCT07153952 — RT for Adenocarcinoma/Adenosquamous Carcinoma · Phase 1, PHASE2 · active not recruiting
- NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04622670 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04622670.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing